UTHR

United Therapeutics Corp
D

UTHR

312.45
USD
5.57
(1.82%)
Market Closed
Volume
10,922
EPS
28
Div Yield
-
P/E
13
Market Cap
14,032,809,704
OverviewSignalsIdeasNews
Related Instruments
AMGN
AMGN
-1.12
(-0.37%)
305.62 USD
BIIB
BIIB
-0.710
(-0.54%)
131.320 USD
BMRN
BMRN
0.380
(0.56%)
68.300 USD
GILD
GILD
0.670
(0.60%)
111.930 USD
INCY
INCY
1.415
(2.32%)
62.320 USD
L
LGND
3.870
(3.70%)
108.360 USD
REGN
REGN
8.56
(1.39%)
625.24 USD
VRTX
VRTX
-1.36
(-0.28%)
483.38 USD
More
News
Treasury Yields Decline as Market Anticipates Fed Rate Cuts

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

7 months ago
Economy News
Novo Nordisk Surges in Profit and Sales

Novo Nordisk Surges in Profit and Sales

11 months ago
Stocks News
Thailand's Economy Stumbles as Regional Peers Improve

Thailand's Economy Stumbles as Regional Peers Improve

11 months ago
Economy News
More

Title: United Therapeutics Corp

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Trading. Social. Simple.
FacebookTwitterYoutube
Company
Contact usAbout usTerms Of UsePrivacy PolicyCookies PolicyDisclaimerHelp Center
Social Network
The NetworkSignals NetworkIdeas NetworkBest Traders
Products
Risk CalculatorPip CalculatorAdvance Chart
Markets
Exchange RatesCommodities RatesCryptocurrencies RatesIndices RatesUS Stocks Rates
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.